Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions

Study summary

This is a clinical trial to evaluate the intravenous administration of indocyanine green (ICG) as a method of intra-thoracic lesion localization. The primary purpose is to determine if intravenous ICG allows us to identify intra-thoracic lesions.

Ask AI to explain this study

Start here

Key things to know

Main goalDevice Feasibility

This describes the study’s primary purpose.

What is being studiedICG Intervention and Near Infrared Camera

The study team can explain what participation involves.

Who it may be forPulmonary Nodule, Solitary · Pulmonary Nodule, Multiple

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 12, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Brigham and Women's Hospital

Study sponsor

Study overview

What this study is about

Purpose: Device Feasibility
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Brigham and Women's Hospital
Interventions being studied: Drug: ICG Intervention; Device: Near Infrared Camera

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients with intra-thoracic lesions that require resection for therapeutic or diagnostic purposes as recommended by their thoracic surgeon.
18 years of age or older
Documented, signed, dated informed consent obtained prior to any study specific procedures being performed

Reasons someone may not be able to joinExclusion criteria

Subjects who do not wish to have subsequent surgical resection
A medical condition such as uncontrolled infection or cardiac disease that, in the opinion of the treating surgeon, makes resection unreasonably hazardous for the patient
Pre-operative spirometry that suggests the patient is at high risk or cannot undergo resection of the primary tumor.
Iodide or seafood allergy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Brigham and Women's HospitalBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 12, 2017. Always confirm current availability with the study team.

View original record ↗